title: Association of plasma pentosidine concentrations with renal function in kidney graft recipients.
abstract: BACKGROUND
  Advanced glycation end-products accumulate in the plasma of uremic patients. We aimed to assess the changes of free (P(free)) and total (P(tot)) plasma pentosidine concentrations in kidney graft recipients, create a model describing their profile and analyze associations with clinical parameters.
  
  
  METHODS
  We measured P(free) and P(tot) in the plasma of 12 non-diabetic patients before and after kidney transplantation by HPLC.
  
  
  RESULTS
  P (tot) concentrations were significantly decreasing after transplantation. The changes were well described by the exponential model assuming an asymptotic fall until the steady-state concentration is attained. P(tot) before and after transplantation displayed a strong negative correlation with mean daily diuresis (Rs = -0.64, p < 0.05 before; Rs = -0.94, p < 0.01 after 20 d). The rate of fall of the P(tot) was positively correlated with the mean daily volume of urine passed in the second week after operation (Rs = +0.58, p < 0.05).
  
  
  CONCLUSIONS
  The rate of fall of the P(tot) after transplantation displays a strong correlation with diuresis, and the P(tot) before transplantation is a potential prognostic factor for diuresis after the operation. Further prospective studies are necessary to demonstrate whether an effort to reduce carbonyl stress and pentosidine concentration before transplantation improves renal outcome.
authors.affiliation: Department of Physiopathology, Pomeranian Medical University, Szczecin, Poland. dorota@sci.pam.szczecin.pl
authors.forename: Dorota
authors.initials: D
authors.lastname: Slowik-Zylka
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Safranow
authors.forename: Violetta
authors.initials: V
authors.lastname: Dziedziejko
authors.forename: Kazimierz
authors.initials: K
authors.lastname: Ciechanowski
authors.forename: Dariusz
authors.initials: D
authors.lastname: Chlubek
mesh_terms: D001120:Arginine / Q000031:analogs & derivatives* / Q000097:blood; D003432:Cross-Linking Reagents / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000628:therapy; D005260:Female; D017127:Glycation End Products, Advanced / Q000378:metabolism*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000601:surgery*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000502:physiology*; D008239:Lysine / Q000031:analogs & derivatives* / Q000097:blood; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D003432:Cross-Linking Reagents; D017127:Glycation End Products, Advanced; D001120:Arginine; C062187:pentosidine; D008239:Lysine